v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Mar. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,419,232 $ 2,715,411
Marketable securities (held at fair value as of March 31, 2026) 2,872,601 2,171,480
Litigation settlement receivable 770,235 0
Other current assets 105,316 113,173
Total current assets 5,167,384 5,000,064
Property and equipment, net 11,986 12,056
Operating lease right-of-use assets 80,416 89,021
Investments measured at fair value 407,985 302,939
Other assets 40,916 32,860
Total assets 5,708,687 5,436,940
Current liabilities:    
Accounts payable 18,002 23,691
Accrued expenses 205,823 114,294
Operating lease liabilities 11,147 9,842
Income tax payable 45,689 416
Other current liabilities 583 1,168
Total current liabilities 281,244 149,411
Liability instruments measured at fair value 0 9,981
Operating lease liabilities, noncurrent 96,291 90,328
Income tax payable, noncurrent 38,670 0
Other liabilities 70 22
Total liabilities 416,275 249,742
Commitments and contingencies (Note 12)
Shareholders’ equity:    
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 720,352,386 and 695,938,323 shares issued and outstanding at March 31, 2026 and 2025, respectively 0 0
Additional paid-in capital 5,024,826 4,562,107
(Accumulated deficit) / retained earnings (501,814) 116,060
Accumulated other comprehensive income 4,358 9,438
Shareholders’ equity attributable to Roivant Sciences Ltd. 4,527,370 4,687,605
Noncontrolling interests 765,042 499,593
Total shareholders’ equity 5,292,412 5,187,198
Total liabilities and shareholders’ equity $ 5,708,687 $ 5,436,940